Glaukos Corp is a healthcare company in the United States that specializes in ophthalmic medical technology. With an ESG score of 19.1, the company is considered low risk. Their focus is on developing innovative products and procedures to revolutionize the treatment of glaucoma. This includes the iStent, a micro-bypass stent used in conjunction with cataract surgery to reduce intraocular pressure in adult patients with open-angle glaucoma. Their product pipeline also includes the iStent SA trabecular micro-bypass system.